Dashboard
Manage Tickers

ANABANAPTYSBIO, INC

Nasdaq anaptysbio.com


$ 23.90 $ 0.58 (2.48 %)    

Monday, 13-May-2024 15:59:26 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 442.84 $ 1.02 (0.23 %)
DIA $ 394.52 $ -0.72 (-0.18 %)
SPY $ 520.61 $ 0.07 (0.01 %)
TLT $ 90.36 $ 0.23 (0.26 %)
GLD $ 216.28 $ -2.45 (-1.12 %)
$ 23.99
$ 23.64
$ 0.00 x 0
$ 0.00 x 0
$ 23.51 - $ 24.60
$ 13.36 - $ 27.50
368,194
na
642.96M
$ 0.66
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-11-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-01-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 03-07-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-04-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 03-02-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 03-05-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-10-2017 06-30-2017 10-Q
29 05-12-2017 03-31-2017 10-Q
30 03-08-2017 12-31-2016 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

the-analyst-landscape-7-takes-on-anaptysbio
The Analyst Landscape: 7 Takes On AnaptysBio
05/10/2024 21:01:14

wedbush-reiterates-outperform-on-anaptysbio-maintains-34-price-target
Wedbush Reiterates Outperform on AnaptysBi...
05/10/2024 13:50:23

Wedbush analyst David Nierengarten reiterates AnaptysBio (NASDAQ:ANAB) with a Outperform and maintains $34 price target.

anaptysbio-q1-2024-adj-eps-164-misses-157-estimate-sales-7180m-beat-3967m-estimate
AnaptysBio Q1 2024 Adj EPS $(1.64) Misses ...
05/09/2024 21:13:12

AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.64) per share which missed the analyst consensus estimate of $(1.57) ...

anaptys-top-line-gemini-2-phase-3-clinical-trial-results-of-imsidolimab-in-generalized-pustular-psoriasis-patients-who-received-a-single-dose-of-750mg-iv-imsidolimab-53-achieved-a-gpp-physician-global-assessment-score-of-01-clear-or-almost-clear-skin-at-week-4
Anaptys Top-Line GEMINI-2 Phase 3 Clinical...
05/09/2024 21:06:19

All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomize...

anaptys-to-receive-50m-upfront-cash-payment-from-sagard-healthcare-from-amended-agreement-in-exchange-for-additional-jemperli-royalties
Anaptys To Receive $50M Upfront Cash Payme...
05/09/2024 21:04:52

Anaptys to receive $50 million upfront cash payment from Sagard Healthcare Prior agreement amended to now expire once Sagard re...

leerink-partners-initiates-coverage-on-anaptysbio-with-outperform-rating-announces-price-target-of-47
Leerink Partners Initiates Coverage On Ana...
04/16/2024 16:10:47

Leerink Partners analyst David Risinger initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Outperform rating and announce...

why-fastenal-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Fastenal Shares Are Trading Lower By A...
04/11/2024 17:33:07

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...

enliven-therapeutics-alpine-immune-sciences-janux-therapeutics-and-other-big-stocks-moving-higher-on-thursday
Enliven Therapeutics, Alpine Immune Scienc...
04/11/2024 14:01:51

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NA...

wells-fargo-initiates-coverage-on-anaptysbio-with-overweight-rating-announces-price-target-of-56
Wells Fargo Initiates Coverage On AnaptysB...
04/11/2024 13:45:48

Wells Fargo analyst Derek Archila initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Overweight rating and announces Pric...

unveiling-4-analyst-insights-on-anaptysbio
Unveiling 4 Analyst Insights On AnaptysBio
04/01/2024 19:01:13

jp-morgan-maintains-neutral-on-anaptysbio-lowers-price-target-to-28
JP Morgan Maintains Neutral on AnaptysBio,...
04/01/2024 14:06:07

JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Neutral and lowers the price target from $30 to $28.

skin-disease-focused-anaptysbio-earns-analyst-upgrade-on-positive-outlook-for-clinical-triggers
Skin Disease-Focused AnaptysBio Earns Anal...
03/12/2024 18:48:52

AnaptysBio exceeds Q4 2023 earnings expectations, with sales of $9.01 million. Expectations high post-Wedbush upgrade, foreseei...

wedbush-upgrades-anaptysbio-to-outperform
Wedbush Upgrades AnaptysBio to Outperform
03/12/2024 11:11:21

Wedbush analyst David Nierengarten upgrades AnaptysBio (NASDAQ:ANAB) from Neutral to Outperform.

anaptysbio-q4-eps-159-beats-160-estimate-sales-901m-beat-223m-estimate
AnaptysBio Q4 EPS $(1.59) Beats $(1.60) Es...
03/11/2024 20:29:02

AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.59) per share which beat the analyst consensus estimate of $(1.60) by...

btig-initiates-coverage-on-anaptysbio-with-buy-rating-announces-price-target-of-55
BTIG Initiates Coverage On AnaptysBio with...
02/26/2024 12:34:14

BTIG analyst Julian Harrison initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Buy rating and announces Price Target of ...

stifel-initiates-coverage-on-anaptysbio-with-buy-rating-announces-price-target-of-50
Stifel Initiates Coverage On AnaptysBio wi...
02/21/2024 10:43:41

Stifel analyst Alex Schwartz initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Buy rating and announces Price Target of ...

anaptysbio-inc--expects-to-report-that-it-had-cash-and-cash-equivalents-and-investments-of-417m-as-of-december-31-2023
AnaptysBio Inc Expects To Report That It ...
01/05/2024 21:20:26

-SEC Filing

wedbush-reiterates-neutral-on-anaptysbio-maintains-20-price-target
Wedbush Reiterates Neutral on AnaptysBio, ...
11/29/2023 13:21:51

Wedbush analyst David Nierengarten reiterates AnaptysBio (NASDAQ:ANAB) with a Neutral and maintains $20 price target.

Core News & Articles
Anaptys Expands Immune Cell Modulator Pipe...
11/27/2023 21:16:34

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfol...

wedbush-maintains-neutral-on-anaptysbio-raises-price-target-to-20
Wedbush Maintains Neutral on AnaptysBio, R...
11/03/2023 13:56:00

Wedbush analyst David Nierengarten maintains AnaptysBio (NASDAQ:ANAB) with a Neutral and raises the price target from $18 to...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION